RESEARCH LABORATORY SETTING英文资料.pdfVIP

UNIVERSITY OF CALIFORNIA SAN FRANCISCO ENVIRONMENTAL HEALTH AND SAFETY/BIOSAFETY VACCINIA (SMALLPOX) IMMUNIZATION POLICY FOR THE RESEARCH LABORATORY SETTING The University of California San Francisco policy on the use of vaccinia virus in research follows national guidelines issued by the Centers for Disease Control and Prevention. This policy has been approved by the Institutional Biosafety Committee (IBC) and is administered by the Office of Environmental Health and Safety (EHS). There are different strains of vaccinia virus with different levels of risk for humans. Standard vaccinia virus was used historically to immunize humans against smallpox, and it is this virus that is still used to immunize humans. This virus can replicate in human cells and thus presents a risk to humans. Recombinant variants of this virus created for experimental purposes present a similar risk to laboratory personnel. Highly attenuated poxvirus strains (MVA, NYVAC, ALVAC, and TROVAC) are unable to replicate or replicate poorly in human cells and do not initiate productive infection in humans. These viruses, often in recombinant form, can also be used for experimental purposes. The recommendations for vaccinia immunization differ depending upon the experimental virus that will be used in the individual laboratory. A. Standard Vaccinia If the laboratory uses standard vaccinia virus or recombinant viruses derived from standard vaccinia virus: 1. All laboratory personnel who directly a) handle cultures or b) inoculate animals with standard vaccinia virus, recombinant vaccinia viruses or other similar orthopoxviruses that infect humans, MUST be vaccinated for Vaccinia (Smallpox) or provide proof of smallpox immunization within the past ten years. In addition, lab personnel must attend a mandatory counseling session with Occupational Health Services prio